Exodus Point Capital Management, LP Kal Vista Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$11.07 - $16.04 $220,580 - $319,613	-19,926 Reduced 57.94%	14,467 $172,000
Q3 2023 Nov 09, 2023	BUY	$8.95 - $11.35 $28,756 - $36,467	3,213 Added 10.3%	34,393 $331,000
Q2 2023 Aug 10, 2023	BUY	$7.73 - $10.57 $241,021 - $329,572	31,180 New	31,180 $281,000
Q4 2021 Feb 11, 2022	SELL	$12.36 - $18.28 $236,978 - $350,482	-19,173 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.11 - $24.49 $328,050 - $469,546	19,173 New	19,173 $335,000
Q4 2019 Feb 14, 2020	SELL	$10.31 - $17.81 $140,216 - $242,215	-13,600 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$11.6 - $21.67 $157,760 - $294,712	13,600 New	13,600 $158,000
Q2 2019 Aug 14, 2019	SELL	$18.44 - $30.89 $428,785 - $718,285	-23,253 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $383,907 - $723,168	23,253 New	23,253 $666,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $229M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.